Arrowhead Pharmaceuticals
ARWRNASDAQTRiM targeted RNAi delivery platform
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
SHASTA-5: Plozasiran in Severe hypertriglyceridemia at high risk of acute pancreatitis — primary completion
2029-03
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
YOSEMITE: Zodasiran in Homozygous familial hypercholesterolemia — primary completion
2027-08-20
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
SHASTA-10: Plozasiran in Hypertriglyceridemia (open-label extension) — primary completion
2028-07
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Plozasiran | familial chylomicronemia syndrome | Approved | Not disclosed | ▼ |
| Fazirsiran | alpha-1 antitrypsin deficiency-associated liver disease | Phase 2 | Not disclosed | ▼ |
| Zodasiran | mixed dyslipidemia | Phase 2 | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium ARWR analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you